The RET proto-oncogene: A molecular therapeutic target in thyroid cancer

Cancer Science

Volumn 96, Issue 3, 2005, Pages 143-148

  Kodama, Yoshinori ^a   Asai, Naoya ^a   Kawai, Kumi ^a   Jijiwa, Mayumi ^a   Murakumo, Yoshiki ^a   Ichihara, Masatoshi ^a   Takahashi, Masahide ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ADENOVIRUS VECTOR; ARTEMIN; CEP 2563; CEP 701; CEP 751; CETUXIMAB; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE P38; MUCIN 1; MUCIN 4; MUCIN 5B; NEURTURIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C GAMMA; PROTEIN BAD; PROTEIN KINASE B; PROTEIN RET; PROTEIN SHC; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RPI 1; STAT3 PROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB;

ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CANCER RESISTANCE; CARCINOGENESIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; GENE IDENTIFICATION; GENE REARRANGEMENT; HUMAN; MOLECULAR CLONING; NEUROFIBROMATOSIS; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTO ONCOGENE; REVIEW; RNA INTERFERENCE; SIDE EFFECT; SIGNAL TRANSDUCTION; SIPPLE SYNDROME; THYROID CANCER; THYROID MEDULLARY CARCINOMA; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; GERM-LINE MUTATION; HUMANS; NEOPLASMS; ONCOGENE PROTEINS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 17744373695     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2005.00023.x     Document Type: Review

References (47)

1. Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 1985; 42: 581-8.
2. Takahashi M, Cooper GM. ret transforming gene encodes a fusion protein homologous to tyrosine kinases. Mol Cell Biol 1987; 7: 1378-85.
3. Takahashi M, Buma Y, Iwamoto T, Inaguma Y, Ikeda H, Hiai H. Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene 1988; 3: 571-8.
4. Jing S, Wen D, Yu Y, Holst PL, Luo Y, Fang M, Tamir R, Antonio L, Hu Z, Cupples R, Louis JC, Hu S, Altrock BW, Fox GM. GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. Cell 1996; 85: 1113-24.
5. Treanor JJ, Goodman L, de Sauvage F, Stone DM, Poulsen KT, Beck CD, Gray C, Armanini MP, Pollock RA, Hefti F, Phillips HS, Goddard A, Moore MW, Buj-Bello A, Davies AM, Asai N, Takahashi M, Vandlen R, Henderson CE, Rosenthal A. Characterization of a multicomponent receptor for GDNF. Nature 1996; 382: 80-3.
6. Airaksinen MS, Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 2002; 3: 383-94.
7. Schuchardt A, D'Agati V, Larsson-Blomberg L, Costantini F, Pachnis V. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature 1994; 367: 380-3.
8. Moore MW, Klein RD, Farinas I, Sauer H, Armanini M, Phillips H, Reichardt LF, Ryan AM, Carver-Moore K, Rosenthal A. Renal and neuronal abnormalities in mice lacking GDNF. Nature 1996; 382: 76-9.
9. Pichel JG, Shen L, Sheng HZ, Granholm AC, Drago J, Grinberg A, Lee EJ, Huang SP, Saarma M, Hoffer BJ, Sariola H, Westphal H. Defects in enteric innervation and kidney development in mice lacking GDNF. Nature 1996; 382: 73-6.
10. Sanchez MP, Silos-Santiago I, Frisen J, He B, Lira SA, Barbacid M. Renal agenesis and the absence of enteric neurons in mice lacking GDNF. Nature 1996; 382: 70-3.
11. Takahashi M. The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev 2001; 12: 361-73.
12. Asai N, Iwashita T, Matsuyama M, Takahashi M. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol 1995; 15: 1613-9.
13. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 1995; 267: 381-3.
14. Iwashita T, Asai N, Murakami H, Matsuyama M, Takahashi M. Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation. Oncogene 1996; 12: 481-7.
15. Jhiang SM. The RET proto-oncogene in human cancers. Oncogene 2000; 19: 5590-7.
16. Alberti L, Carniti C, Miranda C, Roccato E, Pierotti MA. RET and NTRK1 proto-oncogenes in human diseases. J Cell Physiol 2003; 195: 168-86.
17. Putzer BM, Drosten M. The RET proto-oncogene: a potential target for molecular cancer therapy. Trends Mol Med 2004; 10: 351-7.
18. Santoro M, Melillo RM, Carlomagno F, Vecchio G, Fusco A. RET: normal and abnormal functions. Endocrinology 2004.
19. Ichihara M, Murakumo Y, Takahashi M. RET and neuroendocrine tumors. Cancer Lett 2004; 204: 197-211.
20. Asai N, Murakami H, Iwashita T, Takahashi M. A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with shc adaptor proteins. J Biol Chem 1996; 271: 17644-9.
21. Pandey A, Duan H, Di Fiore PP, Dixit VM. The Ret receptor protein tyrosine kinase associates with the SH2-containing adapter protein Grb10. J Biol Chem 1995; 270: 21461-3.
22. Encinas M, Crowder RJ, Milbrandt J, Johnson EM Jr. Tyrosine 981, a novel ret autophosphorylation site, binds c-Src to mediate neuronal survival. J Biol Chem 2004; 279: 18262-9.
23. Borrello MG, Alberti L, Arighi E, Bongarzone I, Battistini C, Bardelli A, Pasini B, Piutti C, Rizzetti MG, Mondellini P, Radice MT, Pierotti MA. The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma. Mol Cell Biol 1996; 16: 2151-63.
24. Hayashi H, Ichihara M, Iwashita T, Murakami H, Shimono Y, Kawai K, Kurokawa K, Murakumo Y, Imai T, Funahashi H, Nakao A, Takahashi M. Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor. Oncogene 2000; 19: 4469-75.
25. Murakami H, Iwashita T, Asai N, Shimono Y, Iwata Y, Kawai K, Takahashi M. Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by ret with the MEN 2B mutation. Biochem Biophys Res Commun 1999; 262: 68-75.
26. Besset V, Scott RP, Ibanez CF. Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase. J Biol Chem 2000; 275: 39159-66.
27. Maeda K, Murakami H, Yoshida R, Ichihara M, Abe A, Hirai M, Murohara T, Takahashi M. Biochemical and biological responses induced by coupling of Gab1 to phosphatidylinositol 3-kinase in RET-expressing cells. Biochem Biophys Res Commun 2004; 323: 345-54.
28. Jijiwa M, Fukuda T, Kawai K, Nakamura A, Kurokawa K, Murakumo Y, Ichihara M, Takahashi M. A targeting mutation of tyrosine 1062 in Ret causes a marked decrease of enteric neurons and renal hypoplasia. Mol Cell Biol 2004; 24: 8026-36.
29. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004; 30: 193-204.
30. Segouffin-Cariou C, Billaud M. Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. J Biol Chem 2000; 275: 3568-76.
31. Murakami H, Yamamura Y, Shimono Y, Kawai K, Kurokawa K, Takahashi M. Role of Dok1 in cell signaling mediated by RET tyrosine kinase. J Biol Chem 2002; 277: 32781-90.
32. Marshall GM, Peaston AE, Hocker JE, Smith SA, Hansford LM, Tobias V, Norris MD, Haber M, Smith DP, Lorenzo MJ, Ponder BA, Hancock JF. Expression of multiple endocrine neoplasia 2B RET in neuroblastoma cells alters cell adhesion in vitro, enhances metastatic behavior in vivo, and activates Jun kinase. Cancer Res 1997; 57: 5399-405.
33. Schuringa JJ, Wojtachnio K, Hagens W, Vellenga E, Buys CH, Hofstra R, Kruijer W. MEN2A-RET-induced cellular transformation by activation of STAT3. Oncogene 2001; 20: 5350-8.
34. Yuan ZL, Guan YJ, Wang L, Wei W, Kane AB, Chin YE. Central role of the threonine residue within the p. +1 loop of receptor tyrosine kinase in STAT3 constitutive phosphorylation in metastatic cancer cells. Mol Cell Biol 2004; 24: 9390-400.
35. Deininger MW. Basic science going clinical: molecularly targeted therapy of chronic myclogenous leukemia. J Cancer Res Clin Oncol 2004; 130: 59-72.
36. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A, Santoro M. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002; 62: 7284-90.
37. Carlomagno F, Vitagliano D, Guida T, Napolitano M, Vecchio G, Fusco A, Gazit A, Levitzki A, Santoro M. The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res 2002; 62: 1077-82.
38. Carlomagno F, Vitagliano D, Guida T, Basolo F, Castellone MD, Melillo RM, Fusco A, Santoro M. Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2). J Clin Endocrinol Metab 2003; 88: 1897-902.
39. Liu Z, Falola J, Zhu X, Gu Y, Kim LT, Sarosi GA, Anthony T, Nwariaku FE. Antiproliferative effects of Src inhibition on medullary thyroid cancer. J Clin Endocrinol Metab 2004; 89: 3503-9.
40. Carniti C, Perego C, Mondellini P, Pierotti MA, Bongarzone I. PP1 inhibitor induces degradation of RET MEN2A and RET MEN2B oncoproteins through proteosomal targeting. Cancer Res 2003; 63: 2234-43.
41. Carlomagno F, Guida T, Anaganti S, Vecchio G, Fusco A, Ryan AJ, Billaud M, Santoro M. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 2004; 23: 6056-63.
42. Strock CJ, Park JI, Rosen M, Dionne C, Ruggeri B, Jones-Bolin S, Denmeade SR, Ball DW, Nelkin BD. CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. Cancer Res 2003; 63: 5559-63.
43. Cuccuru G, Lanzi C, Cassinelli G, Pratesi G, Tortoreto M, Petrangolini G, Seregni E, Martinetti A, Laccabue D, Zanchi C, Zunino F. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. J Natl Cancer Inst 2004; 96: 1006-14.
44. Drosten M, Frilling A, Stiewe T, Putzer BM. A new therapeutic approach in medullary thyroid cancer treatment: inhibition of oneogenic RET signaling by adenoviral vector-mediated expression of a dominant-negative RET mutant. Surgery 2002; 132: 991-7; discussion 997.
45. Drosten M, Stiewe T, Putzer BM. Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model. Hum Gene Ther 2003; 14: 971-82.
46. Roskoski R Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 2004; 319: 1-11.
47. Kawai K, Iwashita T, Murakami H, Hiraiwa N, Yoshiki A, Kusakabe M, Ono K, Iida K, Nakayama A, Takahashi M. Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2A mutation. Cancer Res 2000; 60: 5254-60.